| The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy | |
| Tang, Xiaolong; Li, Qingguo; Zhu, Yongqiang; Zheng, Donghui; Dai, Jingjing; Ni, Wenxuan; Wei, Jia; Xue, Yubao; Chen, Ke; Hou, Wei | |
| 刊名 | AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
 |
| 2015 | |
| 卷号 | 7期号:3 |
| 关键词 | Programmed Death Ligand 1 phosphoinositide 3-kinase cytotoxicity activating chimeric receptor |
| ISSN号 | 1943-8141 |
| URL标识 | 查看原文 |
| 收录类别 | SCIE |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4114875 |
| 专题 | 武汉大学 |
| 推荐引用方式 GB/T 7714 | Tang, Xiaolong,Li, Qingguo,Zhu, Yongqiang,et al. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy[J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH,2015,7(3). |
| APA | Tang, Xiaolong.,Li, Qingguo.,Zhu, Yongqiang.,Zheng, Donghui.,Dai, Jingjing.,...&Liang, Yong.(2015).The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH,7(3). |
| MLA | Tang, Xiaolong,et al."The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy".AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH 7.3(2015). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论